🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: First-line Ribociclib + endocrine therapy

Found 17 matching trials

Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line

PHASE3

This study is designed to evaluate the efficacy and safety of first-line tr...

Status

Completed

Location

Gemeinschaftspraxis für Hämatologie und Onkologie

Start Date

2018-05-24

Trial ID

NCT03462251

Treatments Being Tested

Ribociclib and aromatase inhibitor or fulvestrant Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

This is a prospective study to assess the impact of biomarker driven, early...

Status

Recruiting

Location

Washington University School of Medicine

Start Date

2024-09-25

Trial ID

NCT05977036

Treatments Being Tested

DiviTum® TKa assay CDK4/6 + Endocrine therapy

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

PHASE3

Given the uncertain benefit in efficacy of adding CDK 4/6 to first rather t...

Status

Active Not Recruiting

Location

Jeroen Bosch Ziekenhuis

Start Date

2017-11-09

Trial ID

NCT03425838

Treatments Being Tested

CDK 4/6 inhibitor Non-Steroidal Aromatase Inhibitor Fulvestrant

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

N/A

PALMARES-2 is a retrospective/prospective, observational, multicenter, popu...

Status

Recruiting

Location

Centro di Riferimento Oncologico IRCCS

Start Date

2023-05-01

Trial ID

NCT06805812

Treatments Being Tested

Palbociclib Ribociclib Abemaciclib

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

N/A

This study is being done to determine if there is a pattern associated with...

Status

Recruiting

Location

Mayo Clinic in Florida

Start Date

2024-04-30

Trial ID

NCT06388122

Treatments Being Tested

Biospecimen Collection

First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer

PHASE2

This phase II study focuses on women with rapidly progressive hormone recep...

Status

Completed

Location

Jiangsu Provincial People's Hospital

Start Date

2024-01-09

Trial ID

NCT06375707

Treatments Being Tested

Ribociclib

A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

N/A

This is a non-interventional observational study conducted in Germany to ev...

Status

Completed

Location

Novartis Investigative Site

Start Date

2017-10-09

Trial ID

NCT06311383

Treatments Being Tested

First-line Ribociclib + endocrine therapy First-line endocrine therapy First-line chemtherapy

Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

PHASE3

HARMONIA is an international, multicenter, randomized, open-label and phase...

Status

Terminated

Location

Morton Plant Hospital

Start Date

2022-03-28

Trial ID

NCT05207709

Treatments Being Tested

Ribociclib + Letrozole OR Fulvestrant Palbociclib + Letrozole OR Fulvestrant Paclitaxel +/- Tislelizumab

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

PHASE3

This is a Phase 3, open-label, randomized, clinical trial evaluating the ef...

Status

Recruiting

Location

City of Hope Medical Center

Start Date

2025-07-24

Trial ID

NCT06757634

Treatments Being Tested

Arm A: Gedatolisib + Palbociclib + Fulvestrant Arm B: Ribociclib + Fulvestrant Arm C: Gedatolisib + Palbociclib + Letrozole Arm D: Ribociclib + Letrozole

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

PHASE3

The aim of this trial is to assess if patients treated with the combination...

Status

Terminated

Location

Med. Univ. Klinik Graz

Start Date

2019-06-25

Trial ID

NCT03905343

Treatments Being Tested

Ribociclib Mono-chemotherapy Endocrine-Therapy

Previous Next